The effects of rare sugar on cardiometabolic alterations: a recent update from basic science to clinical application

The main purpose of this review is to explore the potential of rare sugars as an innovative nutritional intervention for obesity-related type 2 diabetes mellitus (T2DM) and associated cardiometabolic diseases. The central research question is whether rare sugars, due to their unique metabolic properties, can serve as effective alternatives to traditional treatments, helping to manage or prevent T2DM while minimizing long-term side effects linked to anti-diabetic drugs.

This review synthesizes evidence from in vitro, ex vivo, in vivo, and clinical studies to assess the effects of rare sugars on glucose metabolism, insulin sensitivity, lipid regulation, and overall cardiometabolic health. Studies were examined for their contributions to understanding the mechanistic pathways and therapeutic implications of rare sugars in comparison with conventional interventions.

Evidence indicates that rare sugars differ significantly from regular sugars in their metabolic impact. Findings highlight their anti-hyperglycemic and anti-hyperlipidemic effects, with demonstrated improvements in insulin sensitivity and glucose regulation. Both animal and human studies suggest that rare sugars may reduce cardiometabolic risks associated with obesity and T2DM, supporting their role as promising functional sweeteners.

Rare sugars present a novel and promising strategy for managing obesity-related T2DM and preventing cardiometabolic complications. While current evidence underscores their beneficial metabolic properties, more comprehensive clinical trials in diverse populations are necessary to validate their efficacy and safety in long-term use. These findings open a pathway for rare sugars to be considered as part of dietary strategies aimed at improving cardiovascular and metabolic health.